Kronos Bio Management
Management criteria checks 3/4
Kronos Bio's CEO is Norbert Bischofberger, appointed in Aug 2018, has a tenure of 6.08 years. total yearly compensation is $1.76M, comprised of 32.9% salary and 67.1% bonuses, including company stock and options. directly owns 21.03% of the company’s shares, worth $12.43M. The average tenure of the management team and the board of directors is 2.6 years and 5.2 years respectively.
Key information
Norbert Bischofberger
Chief executive officer
US$1.8m
Total compensation
| CEO salary percentage | 32.9% |
| CEO tenure | 6.1yrs |
| CEO ownership | 21.0% |
| Management average tenure | 2.6yrs |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being
Jun 20
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?
Jun 11Kronos Bio: Still Promising But Riskier Following ASCO Update
Jun 05Kronos Bio: Underestimated Drug Discovery Platform
May 06Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?
Jan 19We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate
Aug 21We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully
Feb 22Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?
Nov 01Kronos Bio, Invivoscribe to develop companion diagnostic for leukemia drug entospletinib
Aug 16Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?
Jul 07We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely
Feb 01How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?
Mar 03Read This Before Selling Kronos Bio, Inc. (NASDAQ:KRON) Shares
Jan 09
Kronos Bio EPS misses by $4.10
Nov 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$103m |
| Mar 31 2024 | n/a | n/a | -US$116m |
| Dec 31 2023 | US$2m | US$580k | -US$113m |
| Sep 30 2023 | n/a | n/a | -US$119m |
| Jun 30 2023 | n/a | n/a | -US$120m |
| Mar 31 2023 | n/a | n/a | -US$123m |
| Dec 31 2022 | US$3m | US$580k | -US$133m |
| Sep 30 2022 | n/a | n/a | -US$164m |
| Jun 30 2022 | n/a | n/a | -US$165m |
| Mar 31 2022 | n/a | n/a | -US$161m |
| Dec 31 2021 | US$645k | US$320k | -US$151m |
| Sep 30 2021 | n/a | n/a | -US$122m |
| Jun 30 2021 | n/a | n/a | -US$128m |
| Mar 31 2021 | n/a | n/a | -US$108m |
| Dec 31 2020 | US$15m | US$399k | -US$88m |
| Sep 30 2020 | n/a | n/a | -US$61m |
| Jun 30 2020 | n/a | n/a | -US$25m |
| Mar 31 2020 | n/a | n/a | -US$20m |
| Dec 31 2019 | US$280k | US$200k | -US$16m |
Compensation vs Market: Norbert's total compensation ($USD1.76M) is above average for companies of similar size in the US market ($USD677.23K).
Compensation vs Earnings: Norbert's compensation has been consistent with company performance over the past year.
CEO
Norbert Bischofberger (68 yo)
6.1yrs
Tenure
US$1,761,537
Compensation
Dr. Norbert W. Bischofberger, Ph D., is Independent Director of Vir Biotechnology, Inc. from May 29, 2024. He has been an Independent Director of Morphic Holding, Inc. since June 14, 2019.Dr. Bischofberge...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.1yrs | US$1.76m | 21.03% $ 12.4m | |
| Co-Founder & Director | no data | US$74.80k | 0.61% $ 359.2k | |
| Secretary & Director | no data | US$74.80k | 1.52% $ 895.5k | |
| COO & CFO | less than a year | no data | 0.27% $ 161.0k | |
| Vice President of Corporate Development & Investor Relations | 3.3yrs | no data | no data | |
| Senior Vice President of Corporate Operations & Legal | less than a year | no data | 0.34% $ 200.4k | |
| Senior Vice President of Research & Development | 3.7yrs | no data | 0.39% $ 229.9k | |
| Senior Vice President of Clinical Development | 2.6yrs | no data | 0.32% $ 189.4k | |
| Senior Vice President of Drug Discovery & Pharmaceutical Development | 1.4yrs | no data | no data |
2.6yrs
Average Tenure
50yo
Average Age
Experienced Management: KRON's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.4yrs | US$1.76m | 21.03% $ 12.4m | |
| Co-Founder & Director | 7.3yrs | US$74.80k | 0.61% $ 359.2k | |
| Secretary & Director | 7.3yrs | US$74.80k | 1.52% $ 895.5k | |
| Scientific Advisory Board Chairman | no data | no data | no data | |
| Independent Chairman of the Board | 6.8yrs | US$117.20k | 1.13% $ 666.0k | |
| Independent Director | 4yrs | US$89.17k | 0.042% $ 24.8k | |
| Independent Director | 3.5yrs | US$88.70k | 0.019% $ 11.1k | |
| Independent Director | 2.8yrs | US$79.80k | 0% $ 0 | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Independent Director | 1.5yrs | US$105.68k | 0% $ 0 |
5.2yrs
Average Tenure
53yo
Average Age
Experienced Board: KRON's board of directors are considered experienced (5.2 years average tenure).